FBRX News and Press, Forte Biosciences Inc. From 09/20/23

2023-09-20 17:36:12 ET More on Forte Biosciences Forte Biosciences closes $25M financing, to advance FB-102 in 2024 Financial information for Forte Biosciences For further details see: Forte Biosciences rebuke board challengers, re-elect incumbents

Both Leading Independent Proxy Advisory Firms Conclude Forte’s Poor Performance and Dilutive, Anti-Stockholder Actions Under Chairman and CEO Dr. Paul Wagner’s Leadership Indicate Boardroom Change is Urgently Needed Glass Lewis Recommends Stockholders Vote FOR the Gr...

Exposes Misrepresentations and Distortions Included in Forte’s Recent Presentation Encourages Stockholders to Vote for Independent Director Candidates Michael Hacke and Chris McIntyre on the WHITE Proxy Card Ahead of Forte’s Upcoming Annual Meeting on September 19 ...

Highlights Destruction of Nearly 95% in Stockholder Value Under Chairman and CEO Dr. Paul Wagner’s Leadership Exposes Forte’s Worst-in-Class Governance and Repeated Attempts to Use Corporate Machinery as an Entrenchment Tactic, Including Most Recent Private Placement, Ad...

2023-08-14 17:12:40 ET Forte Biosciences press release ( NASDAQ: FBRX ): Q2 Non-GAAP EPS of -$0.42. Forte ended the second quarter 2023 with approximately $30.4 million in cash, cash equivalents and marketable short-term investments. Forte had approximately 21.0 million sh...

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-detailed diseases, today announced second quarter 2023 results and provided a business update. Second Quarter 2023 Business Highlights “We were pl...

2023-08-01 17:09:12 ET Forte Biosciences ( NASDAQ: FBRX ) said Tuesday it closed a $25 million financing to support the advancement of FB-102. The company said it plans to advance FB-102 into the clinic in 2024. The company said FB-102 has demonstrated poten...

-FB-102 Has Demonstrated Potentially Best in Class Activity including Superiority to Standard of Care in GvHD -Proof of Concept Pre-clinical Data in Additional Indications with Large Market Potential Underscores Meaningful Opportunity -$25 Million Financing Highlights Significant ...

Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nas...

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compen...